DS

David Schenkein

General Partner at GV

Boston, Massachusetts

Overview 

David Schenkein is a hematologist and General Partner at GV, with a distinguished career that includes roles as CEO of Agios Pharmaceuticals and Senior Vice President at Genentech. He has made significant investments in companies like Delphia Therapeutics and Encoded Therapeutics, focusing on Series A and Series B stages in the pharmaceutical and biotech sectors. Currently based in Boston, Massachusetts, David Schenkein's career highlights include serving as Chairperson of the Board and CEO at Agios Pharmaceuticals, as well as holding a Senior Vice President position at Genentech.

Work Experience 

G

GV

  • General Partner

    2019 - Current

Google Ventures is an investment arm of Alphabet that provides seed, venture, and growth-stage funding to technology companies.

gv.com
R

Regeneron

  • Board Member

    2023

Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.

Raised $15,931,980.00 from U.S. Department of Health & Human Services.

regeneron.com
TM

Tufts Medical Center

  • Clinical Professor of Medicine

    2009

AP

Agios Pharmaceuticals

  • Board Member

    2022

  • Chairperson of the Board

    2019 - 2022

  • CEO

    2009 - 2019

Agios Pharmaceuticals is a biopharmaceutical company discovers and develops therapeutics in the field of cancer metabolism.

Raised $775,823,937.00 from Celgene, Flagship Pioneering, ARCH Venture Partners and Third Rock Ventures.

agios.com
DT

Denali Therapeutics

  • Board Member

    2015

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Raised $1,122,000,000.00 from Baillie Gifford, ARCH Venture Partners, F-Prime Capital, Flagship Pioneering and Alaska Permanent Fund.

denalitherapeutics.com
G

Genentech

  • Senior Vice President, Clinical Hematology/Oncology

    2006 - 2009

Genentech specializes in genetic testing and personalized medicine.

gene.com

Millennium Pharmaceuticals

  • Senior Vice President, Clinical Research

    2001 - 2006

Education 

Investments 

Delphia Therapeutics

Series A

Total funding: $67M

Cerevance

Series B

Total funding: $160M

EpiBiologics

Series A

Total funding: $96M

Aera Therapeutics

Series B

Total funding: $190M

Articles About David

Relevant Websites